



Respiratory Syncytial Virus (RSV) Vaccines Quick Reference

September 2024

RSV Protection for Infants.

To prevent severe RSV disease in infants, the Centers for Disease Control and Prevention (CDC) recommends either **maternal RSV vaccination** or **infant immunization** with RSV monoclonal antibodies. Most infants will not need both.

Maternal RSV vaccination.

- **Pfizer's Abrysvo is the only RSV vaccine recommended during pregnancy.**
- One dose of maternal RSV vaccine is recommended during gestational weeks 32 and zero days through weeks 36 and six days of pregnancy, administered between September 1 and January 31 of the following year (e.g., Sept. 1, 2024 – Jan. 31, 2025).

Immunization for infants and young children.

Nirsevimab (Beyfortus) is a long-lasting monoclonal antibody product for infants from birth through age 19 months. Beyfortus dosage is determined by the infant's weight and age. There are two presentations of prefilled syringes: 50mg/0.5mL and 100mg/1.0mL. Infants weighing less than five kilograms (less than 11 pounds) receive 50mg/0.5mL. Infants and young children weighing five or more kilograms (greater than or equal to 11 pounds) receive 100mg/1.0mL.

- One dose of nirsevimab is recommended for infants younger than eight months of age who were born shortly before or are entering their **first RSV season**. Ohio's typical RSV season usually starts at the beginning of October and ends the last day of March. **Nirsevimab administration for infants begins October 1 and goes through March 31 of the following year.**
- Nirsevimab is recommended for infants **younger than eight months** of age who were born during or are entering their first RSV season if:
 - The mother did not receive an RSV vaccine during pregnancy.
 - The mother's RSV vaccination status is unknown.
 - The infant was born within 14 days of maternal RSV vaccination.

- Infants and children aged **eight to 19 months** who are at increased risk for severe RSV disease and entering their **second RSV season**, require a 200mg dose of Nirsevimab. This dose is given by using two 100mg/1mL injections (one in each thigh). The following children aged eight months through 19 months who are at increased risk for severe RSV disease are recommended to get a dose shortly before or during their **second RSV season**:
 - American Indian/Alaska Native children.
 - Children with chronic lung disease of prematurity who require medical support during the six months before the start of their second RSV season.
 - Children with severe immunocompromising conditions.
 - Children with severe cystic fibrosis.
- **Children ages eight months and older who are NOT at increased risk of severe RSV disease should NOT receive nirsevimab.**
- Considerations for the use of nirsevimab or palivizumab in infants and young children at increased risk for severe RSV disease are available at [ACIP and AAP Recommendations for the Use of the Monoclonal Antibody Nirsevimab for the Prevention of RSV Disease](#).

RSV Protection for Adults.

To prevent severe RSV disease in adults, CDC recommends the following groups receive an RSV vaccine:

- All adults aged 75 years and older.
- Adults aged 60–74 years who are at increased risk of severe RSV, including:
 - Those with certain chronic medical conditions, such as lung or heart disease.
 - Persons living in a nursing home or congregate setting.
- Only one dose is needed.
 - If an RSV vaccine was received last season, no additional doses are recommended.

There are two sub-protein unit vaccines: Pfizer's Abrysvo and GSK's Arexvy; and one mRNA RSV vaccine: Moderna's mRESVIA.

Resources

Nirsevimab:

- [Nirsevimab Administration Visual Guide](#) (AAP.org).
- [Nirsevimab Frequently Asked Questions](#) (AAP.org).
- [Respiratory Syncytial Virus](#) (*Red Book*).
- [Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection](#) (AAP Technical Report).
- [Nirsevimab Immunization Information Statement](#) (CDC).

Adult RSV ACIP Vaccine Recommendations:

- [RSV Clinical Overview.](#)
- [CDC RSV Website.](#)
- [RSV Vaccine Information Statement.](#)

Contact ODH:

- Phone: (614) 466-4643 or 1-800-282-0546.
- Email: vfc@odh.ohio.gov; Immunize@odh.ohio.gov; Impact@odh.ohio.gov.
- Webpage: [VFC Providers; Ohio ImpactSIIS Help Documents.pdf \(ohiopublichealthreporting.info\)](#).